

UW PACC Psychiatry and Addictions Case Conference UW Medicine | Psychiatry and Behavioral Sciences

CANNABIS AND PTSD RECOVERY: PROBLEM OR SOLUTION?

MICHELE BEDARD-GILLIGAN, PHD UNIVERSITY OF WASHINGTON







GENERAL DISCLOSURES

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.



GENERAL DISCLOSURES

UW PACC is also supported by Coordinated Care of Washington



SPEAKER DISCLOSURES

I, Michele Bedard-Gilligan, have the following commercial relationship to disclose:

My husband is Vice President of Supply Chain for 4Front Ventures, a cannabis company. He leads their non cannabis business.




SPEAKER DISCLOSURES

Michele Bedard-Gilligan, PhD: One financial relationship

PLANNER DISCLOSURES

The following series planners have no relevant conflicts of
interest to disclose:Mark Duncan MDCameron CaseyBarb McCann PhDBetsy PaynAnna Ratzliff MD PhDDiana RollRick Ries MDCara Towle MSN RNKari Stephens PhDNiambi Kanye





CASE EXAMPLE: "STELLA"

- Demographics
 - Cis-gender, heterosexual, married, Caucasian/not hispanic 39 year old woman
 - Employed full-time as a tattoo artist
 - Plays in a band
 - Target trauma: domestic violence (physical & sexual abuse) 20+ years prior
- Clinical Presentation
 - Moderate/severe PTSD symptoms (PSS-I = 40)
 - Diagnosis of past MDD, no current comorbidity
 - Daily cannabis use, reported 0.5 grams/per day over last 30 days
 - Cannabis use: "for PMS, sleeplessness"




OBJECTIVES

- 1. Understand the observed relationships between PTSD and cannabis use
- 2. Explain conceptual models of how cannabis might impact PTSD
- 3. Discuss implications of cannabis use for PTSD recovery and treatment




PTSD IS A PRIMARY REASON THAT INDIVIDUALS SEEK OUT CANNABIS IN STATES THAT HAVE LEGALIZED MEDICAL CANNABIS (BOWLES, 2012)






CANNABIS USE AND CANNABIS USE DISORDER (CUD) ARE INCREASING IN THE US POPULATION






RATES OF CANNABIS USE ARE INCREASING IN THOSE SEEKING TREATMENT FOR PTSD

2004 - 2010



Cannabis UseNo Cannabis Use

2011 - 2016




Cannabis UseNo Cannabis Use



R01MH066347, R01MH066348, R01MH066347

WHY DO PATIENTS WITH PTSD USE CANNABIS? SELF-MEDICATION THEORY






KEY BRAIN AREAS IMPLICATED IN CANNABIS USE

Targeting the endocannabinoid system as treatment for PTSD (Berardi et al., 2016; Korem et al., 2015; Trezza & Campoglona, 2013) Cannabinoid

receptors (CB_1) are implicated in processing of fear, stress, emotion, and reward in the brain



Cerebral cortex

thinking, perceptual awareness and	men			
	thin	ong		
awareness and	perc	epti	ıal	
	awa	rene	55.8	nd

Altered consciousness; perceptual distortions; memory impairment; occasional delusions and hallucinations

Increased

appetite

Hypothalamu

Governs metabolic processes such as appetite

Brain stem

Controls many Nausea relief; basic functions rapid heart rate; including reduced blood arousal, the pressure; vomiting reflex, drowsiness blood pressure and heart rate

Also plays a Pain reduction; role in pain reduced sensation, spasticity; muscle tone and reduced tremor movement

lippocamp

Is key to Impairment in memory storage memory and recall

Cerebellum


Governs coordination and muscle control Reduced spasticity; impaired coordination

Amygdala

Plays a role in emotions reduced anxiety and blocking of traumatic memories in other cases; reduced hostility



©2020 University of Washington



CANNABIS AS A POTENTIAL TREATMENT FOR PTSD?

- Potential therapeutic benefits
 - Manage the emotional symptoms (e.g., capitalize on anxiolytic effects of cannabis)
 - Increase the process of new learning associated with recovery (i.e., extinction enhancer)





PTSD IS THE PERSISTENCE OF MALADAPTIVE REACTIONS, NOT THE MERE PRESENCE OF REACTIONS


Failure in natural fear extinction thought to be key mechanism in the persistence of PTSD

Mahan & Ressler, 2012



HOW MIGHT CANNABIS RELATE TO FEAR EXTINCTION?

Fear extinction



- Facilitation effect:
 - CB₁ receptors in the ventromedial prefrontal cortex and hippocampus
 - These areas are heavily implicated in extinction learning (e.g., Bouton et al., 2006; Milad et al., 2008)

Detrimental effect:

- Documented amotivational and anxiolytic effects
- Biphasic effects anxiolytic vs anxiogenic (D'Souza et al., 2004; Viveros et al., 2005)
- Acute impairments on learning, memory, attention, and working memory (Volkow et al., 2016)




PSYCHOTHERAPIES BASED ON EXTINCTION LEARNING HAVE LARGE EFFECTS IN DECREASING PTSD SYMPTOMS

		Effect Size
Intervention	N	<i>(g)</i>
All Psychotherapies	76	1.14
Cognitive Therapies	10	1.63
Exposure Therapies	27	1.08
Mixed Cognitive and Exposure	14	1.38
EMDR	11	1.01
All Medications	56	0.42
SSRIs	20	0.48

 \bigcirc

HUMAN STUDIES OF THC AND EXTINCTION

- Administration of THC facilitated short-term extinction as evidenced by decreased skin conductance response when tested 24 hours later (Rabinak et al., 2013)
 THC prevented the recovery of fear
- Facilitation may be limited to acute effects (Klumpers et al., 2012)
- Studies were done in healthy, cannabis naïve volunteers






CHRONIC CANNABIS USERS SHOW DEFICITS IN EXTINCTION LEARNING

- Reduced within-session


 (d = 0.78) and between
 session (d = 0.76)
 extinction, as measured
 by skin conductance
 response
- Suggests chronic cannabis use impairs, not facilitates, extinction






CANNABIS IS ASSOCIATED WITH HIGHER DROPOUT IN A CLINICAL TRIAL OF AN EXTINCTION-BASED PTSD THERAPY

- In clinical practice, cannabis use may impair PTSD treatment response to an extinction based treatment
- In our clinical trial (N = 200; R01MH066347/R01MH066348) cannabis use predicted
 - Higher likelihood of dropout






CANNABIS USE ALSO ASSOCIATED WITH LESS PTSD RECOVERY IN THAT SAME TRIAL



Bedard-Gilligan et al., 2018


EFFECTS OF CANNABIS ON RECOVERY ARE UNCLEAR





THE FUNCTION OF CANNABIS: PATIENT VIEWS

- Patients perceive clinical benefits to their cannabis use
 - "Marijuana makes it so I do not have to take any heavy narcotic pain medications"
 - "Marijuana replaces an obscene amount of things that I have been prescribed and tried in the past with less successful results"
 - "I use it to calm my anxiety and focus more on self-care"



Diverse reasons for cannabis use (N = 17)




ONGOING TRIAL OF EXPOSURE THERAPY FOR PTSD AND CANNABIS USE (R34 DA040034)

- Key questions/issues:
 - Does cannabis use get in the way of treatment?
 - How does it affect engagement and fear extinction?
 - How does it affect cognitive ability to process?
 - Does cannabis use change with treatment?




WITHIN SESSION EXTINCTION PATTERNS BY CANNABIS USE GROUP (*N* = 31)






BETWEEN SESSION EXTINCTION PATTERNS BY CANNABIS USE GROUP (N = 31)






CASE EXAMPLE "STELLA": HIGHER COGNITIVE FUNCTIONING DURING PROCESSING?



Session 5					
PTSD (PSS-SR)	22				
Depression (QIDs)	14				
Time since last cannabis use	1 hour				
Perceived high	2/10				
Strain	Strawberry Banana Sherbert				
Pre-SUDs	30				
Post-SUDs	15				



CHANGES IN PTSD SYMPTOMS AND TRAUMA RELATED COGNITIONS FOR "STELLA"






"STELLA'S" PRE TO FOLLOW-UP CANNABIS USE

Pre-Tx TLFB Cannabis Use

 \bigcirc

1.50	-	- /	-	24	23	20	21
	28	29	30 5	31).5	1,5	2.5	3.5
F	⁴.S	* . S	6.5	4,5	8,5	۰.5	10.5
E	",5	12.5	¹³ .5	14 valentine's bay	15,5	16°°, 5	¹⁷ , 5
В	18 . 5	19 President's bay	20 ,5	21.5	22 .S	23.5	24 .5
	²⁵ ,5	26,5	27.5 (28.5	1	2	3

Follow-up TLFB Cannabis Use





PERSONALIZING TREATMENTS

- One size fits all approach to treatment means we are missing important subgroups
- Meeting patients "where they are at"
- Many using cannabis may not seek or comply with treatment that requires reductions/abstinence in use
- Doesn't mean we need to abandon treatments we know work
- Simple treatment adjustments may improve adherence and create hope
 - Fewer sessions in compressed time frame with no HW



CANNABIS AND PTSD: PROBLEM OR SOLUTION?






RT @CONSPIRACY_FACT: https://t.co/m9V8bBSBD3











REFERENCES

Bedard-Gilligan, M., Garcia, N., Zoellner, L., & Feeny, N. (2018). Alcohol, Cannabis, and Other Drug Use: Engagement and Outcome in PTSD Treatment. *Psychology of Addictive Behaviors, 32*(3), 277 288. PMCID pending.

Bonn-Miller, M. O., Babson, K. A., Vujanovic, A. A., & Feldner, M. T. (2010). Sleep problems and PTSD symptoms interact to predict marijuana use coping motives: A preliminary investigation. *Journal of Dual Diagnosis*, 6(2), 111-122.

Bouton, M. E., Westbrook, R. F., Corcoran, K. A., & Maren, S. (2006). Contextual and temporal modulation of extinction: behavioral and biological mechanisms. *Biological Psychiatry*, 60(4), 352 360.

Bremner, J. D., Southwick, S. M., Darnell, A., & Charney, D. S. (1996). Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. The American Journal of Psychiatry, 153, 369-375.

Cornelius, J. R., Kirisci, L., Reynolds, M., Clark, D. B., Hayes, J., & Tarter, R. (2010). PTSD contributes to teen and young adult cannabis use disorders. Addictive Behaviors, 35(2), 91-94.

Cougle, J. R., Bonn-Miller, M. O., Vujanovic, A. A., Zvolensky, M. J., & Hawkins, K. A. (2011). Posttraumatic stress disorder and cannabis use in a nationally representative sample. *Psychology of Addictive Behaviors*, 25(3), 554-558.

D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., ... & Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology*, 29(8), 1558-1572.

Hasin, D.S., Saha, T.D., Kerridge, B.T., Goldstein, R.B., Chou, S.P., Zhang, H., et al. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72,1235-42. [PMID: 26502112] doi:10.1001/jamapsychiatry.2015.1858

Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., & Baas, J. M. (2012). Testing the effects of Δ9-THC and D-cycloserine on extinction of conditioned fear in humans. Journal of Psychopharmacology, 26(4), 471-478.

Milad, M. R., Orr, S. P., Lasko, N. B., Chang, Y., Rauch, S. L., & Pitman, R. K. (2008). Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. *Journal of Psychiatric Research*, 42(7), 515-520.

Papini, S., Ruglass, L. M., Lopez-Castro, T., Powers, M. B., Smits, J. A., & Hien, D. A. (2017). Chronic cannabis use is associated with impaired fear extinction in humans. *Journal of Abnormal Psychology*, 126(1), 117.

Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013). Cannabinoid facilitation of fear extinction memory recall in humans. *Neuropharmacology*, *64*, 396-402.

Viveros, M. P., Marco, E. M., & File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry and Behavior, 81(2), 331-342.

Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., ... & Baler, R. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry, 73(3), 292-297.

